AU2002215109A1 - Novel use of certain insulin sensitizers or ppar-gamma agonists - Google Patents

Novel use of certain insulin sensitizers or ppar-gamma agonists

Info

Publication number
AU2002215109A1
AU2002215109A1 AU2002215109A AU1510902A AU2002215109A1 AU 2002215109 A1 AU2002215109 A1 AU 2002215109A1 AU 2002215109 A AU2002215109 A AU 2002215109A AU 1510902 A AU1510902 A AU 1510902A AU 2002215109 A1 AU2002215109 A1 AU 2002215109A1
Authority
AU
Australia
Prior art keywords
ppar
novel use
insulin sensitizers
gamma agonists
certain insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215109A
Inventor
Robin Edwin Buckingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2002215109A1 publication Critical patent/AU2002215109A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2002215109A 2000-11-14 2001-11-14 Novel use of certain insulin sensitizers or ppar-gamma agonists Abandoned AU2002215109A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0027783.0 2000-11-14
GBGB0027783.0A GB0027783D0 (en) 2000-11-14 2000-11-14 Novel use
PCT/GB2001/005044 WO2002040020A1 (en) 2000-11-14 2001-11-14 Novel use of certain insulin sensitizers or ppar-gamma agonists

Publications (1)

Publication Number Publication Date
AU2002215109A1 true AU2002215109A1 (en) 2002-05-27

Family

ID=9903156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215109A Abandoned AU2002215109A1 (en) 2000-11-14 2001-11-14 Novel use of certain insulin sensitizers or ppar-gamma agonists

Country Status (6)

Country Link
US (1) US20040266833A1 (en)
EP (1) EP1335724A1 (en)
JP (1) JP2004513923A (en)
AU (1) AU2002215109A1 (en)
GB (1) GB0027783D0 (en)
WO (1) WO2002040020A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060056377A (en) * 2003-08-13 2006-05-24 카이론 코포레이션 Gsk-3 inhibitors and uses thereof
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476865A (en) * 1994-07-06 1995-12-19 Eli Lilly And Company Methods of inhibiting bone loss
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US6239157B1 (en) * 1999-09-10 2001-05-29 Osiris Therapeutics, Inc. Inhibition of osteoclastogenesis

Also Published As

Publication number Publication date
EP1335724A1 (en) 2003-08-20
WO2002040020A9 (en) 2003-11-13
US20040266833A1 (en) 2004-12-30
JP2004513923A (en) 2004-05-13
GB0027783D0 (en) 2000-12-27
WO2002040020A1 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2002226486A1 (en) Novel c-glycoside derivatives and use thereof
AU2710301A (en) Novel remedies with the use of beta3 agonist
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2002226487A1 (en) Novel c-glycoside derivatives and use thereof
AU2001291859A1 (en) Use of copolycarbonates
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2002350228A1 (en) Antisense modulation of myd88 expression
AU2003268096A1 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU2002320525A1 (en) Antisense modulation of glioma-associated oncogene-2 expression
AU2003239579A1 (en) Antisense modulation of vegf-c expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2001239246A1 (en) Novel use of herbicides
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2002217071A1 (en) Novel use of polyhydroxy compounds
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU2001287136A1 (en) Antisense modulation of glioma-associated oncogene-1 expression
AU2003288898A1 (en) Antisense modulation of endothelial specific molecule 1 expression
AU2002215109A1 (en) Novel use of certain insulin sensitizers or ppar-gamma agonists
AU2001248840A1 (en) Novel collectins
AU2002213420A1 (en) Single-use syringe
AU2002322551A1 (en) Antisense modulation of rip2 expression
AU2001295951A1 (en) Novel 4-benzyloxyphenyl derivative and use thereof